Development in therapeutic strategies for allergic conjunctivitis

Conjunctivitis, also known as pink eye, is a conjunctival inflammation. It brought on by bacteria, viruses, toxins, and allergies, including coronaviruses, the most frequent reason being allergic conjunctivitis (AC), which exposure to pollutants like pollen, animal hair, or mold. The primary contributor it linkage of immunoglobulin E caused allergens receptors stimulated mast cells. As consequence, cells are degranulated, along with release histamine, cytokines, chemokines, lipid mediators. particular eye tissues impacted immune mechanism(s) (both local systemic) that involved all play role in clinical course, length, intensity, co-morbidities. frequently occurs conjunction rhinitis, rhino-conjunctivitis other allergy conditions. Atopic keratoconjunctivitis, giant papillary conjunctivitis, seasonal perennial vernal keratoconjunctivitis different types conjunctivitis. Ocular allergies misdiagnosed undertreated, despite emergence innovative therapeutic strategies. This review focuses several previously published studies discuss available options for treating well potential targets therapies. association COVID-19, recent patents research, has been explored.